Cipla Limited
CIPLAStructural risk assessment following Q4-FY26 | 31 Mar 26 earnings.
Q3-FY26 | 31 Dec 25
16
Risk Score
Q4-FY26 | 31 Mar 26
48
Risk Score
🔴Risk increased by +32 points
Flagium detected:
- ⚠Profit Collapse
- ⚠Margin Compression
- ⚠Relative Growth Weakness
- ⚠Inventory Stress
ℹ️ Executive Summary
Cipla Limited registered a drop in both quarterly revenue and net profit, reflecting challenging industry-wide demand trends. A 'Moderate Deterioration' risk classification and 6 active flags indicate that operating headwinds are beginning to translate into structural pressure.
🛡️ Sentinel Insight
"Cipla Limited currently sits within Flagium's Moderate Deterioration category. However, recent periods have introduced early signs of competitive and operating pressure, leverage and funding pressure. With both revenue and profit contracting, triggers like 'Profit Collapse', 'Margin Compression' amplify the structural risk. The combination of active triggers indicates escalating structural vulnerabilities that require active monitoring."
The Quarter at a Glance
| Metric | Q4-FY26 | 31 Mar 26 | Q4-FY25 | 31 Mar 25 | Change |
|---|---|---|---|
| Revenue | ₹6,689.4 Cr | ₹7,019.1 Cr | -4.7% |
| EBIT Margin | 10.57% | 21.43% | -1086 bps |
| Net Profit (PAT) | ₹542.5 Cr | ₹1,214.1 Cr | -55.3% |
| Interest Expense | ₹13.1 Cr | ₹14.0 Cr | -6.3% |
← scroll to see all →
What Changed Beneath the Headlines?
Revenue Contraction
Quarterly revenue changed by -4.7% YoY, reflecting demand and volume updates.
Net Profit Compression
Profit after tax changed by -55.3% YoY, settling at ₹542.5 Cr.
Operating Margins
Operating margin declined by 1086 bps YoY to 10.57%.
Flagium Risk Signals
CIPLA: Net Profit collapsed by 55.3% from FY2025 Q4 to FY2026 Q4.
Operating margin declined by 10.9 bps YoY for two consecutive quarters.
Revenue growth consistently lags behind sector median (12.8%).
Inventory growth (16.9%) significantly outpaced revenue growth (-4.7%).
Working capital expansion detected: Receivable days increased by 7.1%.
Expenses are consistently growing faster than revenues, creating operational pressure.
What the financials are implicitly signaling
Flagium's structural analysis indicates:
- •Margin defense remains a priority as raw material costs or operating expense pressures rise.
- •Deleveraging or structural balance sheet adjustment is required to defend interest coverage ratios.
- •Demand visibility remains weak, leading to a focus on volume conservation over pricing power.
Signals to Monitor Next Quarter
Resolution of 'Profit Collapse' warning: CIPLA: Net Profit collapsed by 55.3% from FY2025 Q4 to FY2026 Q4.
Resolution of 'Relative Growth Weakness' warning: Revenue growth consistently lags behind sector median (12.8%).
Resolution of 'Inventory Stress' warning: Inventory growth (16.9%) significantly outpaced revenue growth (-4.7%).
Resolution of 'Operating Leverage Stress' warning: Expenses are consistently growing faster than revenues, creating operational pressure.
Historical Quality Trend
Last 6 Quarters| Quarter | Risk Score | Trend | Current Risk Class |
|---|---|---|---|
| Q4 FY26 | 48 | ↑ | 🔵 Moderate Deterioration |
| Q3 FY26 | 16 | ↑ | 🟢 Stable |
| Q2 FY26 | 11 | ↑ | 🟢 Stable |
| Q1 FY26 | 10 | ↑ | 🟢 Stable |
| Q4 FY25 | 5 | ↑ | 🟢 Stable |
| Q3 FY25 | 0 | → | 🟢 Stable |
← scroll to see all →
What to do next
Explore CIPLA's full structural risk profile — 12Q score trajectory, pillar breakdown, flag history, and peer benchmarking.
View CIPLA profile →See how Pharmaceuticals peers and the broader market are positioned. Identify sector-wide stress or rotation signals.
Open market monitor →Check how this Q4-FY26 | 31 Mar 26 result affects your portfolio's overall risk exposure and concentration.
Review your portfolio →Disclaimer
Flagium AI is an automated financial data analytics platform. Analysis reports are compiled programmatically from public regulatory XBRL submissions (NSE/BSE). This evaluation does not constitute investment advice, financial planning, or recommendations to buy, sell, or hold any security. Please consult a SEBI-registered investment advisor before acting on any data presented.